YOU RECENTLY RECEIVED A NOTIFICATION REGARDING AN SGLT2I OR GLP-1 PRESCRIPTION FOR A T2D-RELATED GLYCEMIC CONTROL AGENT YOU WROTE FOR A SMITHRX MEMBER.
Consider prescribing Brenzavvy®—the affordable SGLT2i for glycemic control in type 2 diabetes (T2D) for your clinically appropriate patients* with SmithRx.
1
Retail Pharmacy
Send a prescription for BRENZAVVY to the patient’s preferred retail pharmacy.
2
Mail Order Delivery
For convenient mail order delivery: Cost Plus Drugs or Amazon Pharmacy
Questions?
Contact SmithRx: If you have any questions or need further assistance, including patient coverage or sending a new prescription for BRENZAVVY, please contact the SmithRx Connect team at 844-385-7612.
$
0
Patient Co-pay for Your Patients Prescribed Brenzavvy for Glycemic Control in T2D
What is BRENZAVVY?
BRENZAVVY (bexagliflozin) is an SGLT2 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Not recommended for use in patients with type 1 diabetes mellitus. (refs 1-4)
BRENZAVVY has demonstrated (ref 1):
-
Significant improvement in glycemic control
-
Decreases in body weight and systolic blood pressure
-
Effective in adults with type 2 diabetes and stage 3 (3a + 3b) chronic kidney disease
What is the cost to patients?
$
0
co-pay to reduce cost barriers and to improve adherence
-
A $0 co-pay for BRENZAVVY is consistent with the direct-to-consumer pricing models emerging in the pharmaceutical industry that prioritize patient affordability and supports greater adherence for chronic condition treatment.
-
Substantial Plan Savings: The cost to the patient’s employer is significantly lower compared to other SGLT2is and GLP-1s in the class (ranging from $600 to $60).
Brenzavvy®
(bexagliflozin)
Mfg List Price‡
$50
Average OOP§ for SmithRx Members
$0
Jardiance®
(empagliflozin) (ref 5)†
PA Required
Mfg List Price‡
$629
Average OOP§ for SmithRx Members
$64.77||
Farxiga®
(dapagliflozin) (ref 6)†
PA Required
Mfg List Price‡
$599
Average OOP§ for SmithRx Members
$48.05¶
Invokana®
(canagliflozin) (ref 7)
PA Required
Mfg List Price‡
$548
Average OOP§ for SmithRx Members
$51.67#
Glycemic Control Agents:
PA Required
Typical Mfg List Price From‡
$250
With Average Co-pay Over
$50
Cost does not imply a comparison of efficacy or safety.
* Not indicated for patients with coexisting chronic kidney disease (CKD)
† Cost based on a 30-day supply
‡ List prices are subject to change and are accurate as of 11/24/25.
§ Average patient out-of-pocket cost, including co-pay
|| Based on a 30-day supply at 10mg of JARDIANCE for SmithRx members
¶ Based on a 30-day supply at 10mg of FARXIGA for SmithRx members
# Based on a 30-day supply at 100mg of INVOKANA for SmithRx members
Who should not take BRENZAVVY?
Do not take BRENZAVVY if you are allergic to bexagliflozin or any of the ingredients in BRENZAVVY. Symptoms of a serious allergic reaction to BRENZAVVY may include a skin rash, raised red patches on your skin (hives), and swelling of the face, lips, tongue, and throat that may cause difficulty in breathing or swallowing.
References:
-
BRENZAVVY [prescribing information]. Framingham, MA: TheracosBio, LLC.
-
Xie D, Zhang W, Wei Y, et al. Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: A 24-week, randomized, double-blind, active-controlled, phase 3 trial. J Diabetes. 2024;16(4):e13526.
-
Allegretti AS, Zhang W, Zhou W, et al. Safety and effectiveness of bexagliflozin in patients with type 2 diabetes mellitus and stage 3a/3b CKD. Am J Kidney Dis. 2019;74(3):328-337.
-
McMurray JJV, Freeman MW, Massaro J, et al. The Bexagliflozin Efficacy and Safety Trial (BEST): A Randomized, Double-Blind, Placebo-Controlled, Phase IIII, Clinical Trial. Diabetes. 2020;69(suppl 1):32-OR.
-
JARDIANCE [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.
-
FARXIGA [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals.​
-
INVOKANA [prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.
Copyright 2026 QC-Health, Inc. All rights reserved.